Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 150
- Registration Number
- NCT03204799
- Locations
- 🇰🇷
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center, Seoul, Korea, Republic of
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 20
- Registration Number
- NCT03105310
Ezetimibe for Patients With Chronic Hepatitis D
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Ziauddin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03099278
- Locations
- 🇵🇰
Ziauddin University Hospital, Karachi, Sindh, Pakistan
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 269
- Registration Number
- NCT03001076
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT02984982
- Locations
- 🇯🇵
Investigational Site Number 392008, Gifu-shi, Japan
🇯🇵Investigational Site Number 392022, Chiyoda-ku, Japan
🇯🇵Investigational Site Number 392039, Hiroshima-shi, Japan
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT02890992
- Locations
- 🇨🇿
Investigational Site Number 2030002, Zlin, Czechia
🇺🇸Investigational Site Number 8400005, Charlotte, North Carolina, United States
🇺🇸Investigational Site Number 8400001, Cincinnati, Ohio, United States
Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Pontificia Universidad Catolica de Chile
- Target Recruit Count
- 12
- Registration Number
- NCT02768545
- Locations
- 🇨🇱
Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, RM, Chile
A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 396
- Registration Number
- NCT02749994
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 135
- Registration Number
- NCT02748057
A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 66
- Registration Number
- NCT02730689
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.